Extended treatment with single-agent ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia/small lymphocytic lymphoma

PURPOSE: Ibrutinib, a first-in-class, once-daily, oral inhibitor of Bruton’s tyrosine kinase, promotes apoptosis, and inhibits B-cell proliferation, adhesion, and migration. Ibrutinib has demonstrated single-agent efficacy and acceptable tolerability at doses of 420 and 840 mg in patients with chron...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Coutré, Steven E., Furman, Richard R, Flinn, Ian W., Burger, Jan A., Blum, Kristie, Sharman, Jeff, Jones, Jeffrey, Wierda, William, Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Tran, Anh, Zhou, Cathy, Bilotti, Elizabeth, James, Danelle F., Byrd, John C., O’Brien, Susan
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6317338/
https://ncbi.nlm.nih.gov/pubmed/28073846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1431
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados